NASDAQ$LXRX
Lexicon Pharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Lexicon Pharmaceuticals reported financial results for Q2 2023 and provided a business update.
Lexicon Pharmaceuticals reported a net loss of $44.9 million, or $0.22 per share, for the second quarter of 2023. The company received FDA approval for INPEFA and commercially launched it in the U.S. LX9211 is moving into late-stage development for diabetic peripheral neuropathic pain.
- INPEFA (sotagliflozin) received FDA approval for the treatment of heart failure.
- INPEFA was granted a broad label across the full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes.
- LX9211 is moving into late-stage development for the treatment of diabetic peripheral neuropathic pain.
- Lexicon commercially launched INPEFA in the U.S. within 30 days of FDA approval.
Headline financials
Revenue & EPS history
Lexicon Pharmaceuticals · Revenue · Quarterly
$317K
Revenue by segment
Lexicon Pharmaceuticals · $317K total across 2 segments · Q2 2023
- Net Product Revenue$291K—91.8%
- Royalties and Other$26K-25.7%8.2%
Forward guidance
This press release contains forward-looking statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates.
Tailwinds
- Lexicon's ability to meet its capital requirements.
- Successfully commercialize its approved products.
- Successfully conduct preclinical and clinical development
- Obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines
- Achieve its operational objectives
Headwinds
- Manufacturing risks
- Intellectual property rights risks
- Therapeutic value risks
- Commercial value risks
- Risks relating to strategic alliances
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
-0.4%
Avg return
30 days after
56%
36 / 64 earnings
Positive
+30.6%
Q3 2015
Best reaction
-26.0%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.4% | +50.0% | +19.4% | |
| Q4 2025 | -0.6% | +1.8% | -2.5% | |
| Q3 2025 | +3.0% | +13.0% | +1.4% | |
| Q1 2025 | +3.1% | +22.2% | +24.1% | |
| Q4 2024 | +6.6% | +2.7% | +13.5% | |
| Q3 2024 | -14.2% | -22.8% | -35.4% | |
| Q2 2024 | -24.4% | -27.1% | -23.1% | |
| Q1 2024 | +5.5% | +7.3% | +3.0% | |
| Q4 2023 | +16.1% | +19.8% | -6.9% | |
| Q3 2023 | -17.2% | -14.4% | +0.0% | |
| Q2 2023 | -1.1% | -3.7% | -10.6% | |
| Q1 2023 | +12.3% | +43.0% | +11.1% | |
| Q4 2022 | +21.8% | +17.3% | +10.5% | |
| Q3 2022 | +8.7% | +13.1% | -1.0% | |
| Q2 2022 | +13.5% | +19.4% | +16.5% | |
| Q1 2022 | -7.2% | -9.8% | -6.7% | |
| Q4 2021 | -26.0% | -25.3% | -26.3% | |
| Q3 2021 | -11.2% | -9.8% | -25.5% | |
| Q2 2021 | +2.0% | -4.7% | +28.8% | |
| Q1 2021 | -0.4% | -3.7% | -3.5% | |
| Q4 2020 | -1.4% | -2.6% | -23.8% | |
| Q3 2020 | -9.0% | -9.8% | +32.8% | |
| Q2 2020 | +11.5% | +12.6% | +0.0% | |
| Q1 2020 | +3.4% | -7.3% | -1.0% | |
| Q4 2019 | -10.6% | +3.5% | -17.2% | |
| Q3 2019 | -8.6% | -8.8% | +26.5% | |
| Q2 2019 | -21.1% | -19.9% | -20.5% | |
| Q1 2019 | +4.7% | +20.9% | -7.2% | |
| Q4 2018 | +2.2% | +6.3% | -15.3% | |
| Q3 2018 | +8.4% | +8.8% | +3.4% | |
| Q2 2018 | -3.0% | -11.8% | -6.2% | |
| Q1 2018 | +8.4% | +17.3% | +52.2% | |
| Q4 2017 | +1.3% | +4.5% | -1.3% | |
| Q3 2017 | -6.3% | +0.8% | +8.4% | |
| Q2 2017 | -4.4% | -3.7% | -7.1% | |
| Q1 2017 | +2.4% | +2.2% | -9.5% | |
| Q4 2016 | +9.0% | +11.0% | -4.8% | |
| Q3 2016 | -4.2% | -3.0% | -1.3% | |
| Q2 2016 | +1.6% | +0.6% | -11.8% | |
| Q1 2016 | -15.6% | — | — | |
| Q4 2015 | +24.4% | — | — | |
| Q3 2015 | +30.6% | — | — | |
| Q2 2015 | -8.6% | — | — | |
| Q1 2015 | -5.7% | — | — | |
| Q4 2014 | +14.3% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | -6.6% | — | — | |
| Q1 2014 | +1.4% | — | — | |
| Q4 2013 | +3.8% | — | — | |
| Q3 2013 | -2.6% | — | — | |
| Q2 2013 | +7.8% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +1.9% | — | — | |
| Q3 2012 | -9.6% | — | — | |
| Q2 2012 | +3.7% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q4 2011 | +5.6% | — | — | |
| Q3 2011 | -9.9% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +1.9% | — | — | |
| Q4 2010 | +6.3% | — | — | |
| Q3 2010 | -3.7% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2010 | +8.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro